7. Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, et al. (2010) Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 57: 152–157. 8. Dancer JY, Truong LD, Zhai Q, Shen SS (2010) Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 134: 90–94. 9. Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, et al. (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31: 277–285. 10. van den Brule FA, Berchuck A, Bast RC, Liu FT, Gillet C, et al. (1994) Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer 30A: 1096–1099. 11. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, et al. (1996) Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27: 1185–1191. 12. Castronovo V, van den Brule FA, Jackers P, Clausse N, Liu FT, et al. (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179: 43–48. 13. Idikio H (1998) Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12: 1287–1290. 14. Lee JW, Song SY, Choi JJ, Choi CH, Kim TJ, et al. (2006) Decreased galectin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol 132: 241–247. 15. Schoeppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75: 2818–2826. 16. Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, et al. (1999) Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15: 143–148. 17. Irimura T, Matsushita Y, Sutton RC, Carralero D, Ohannesian DW, et al. (1991) Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 51: 387–393. 18. Sanjuan X, Fernandez PL, Castells A, Castronovo V, van den Brule F, et al. (1997) Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology 113: 1906–1915. 19. Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, et al. (1992) Inverse modulation of steady-state messenger RNA levels of two non- integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84: 1161–1169. 20. Lotz MM, Andrews CW, Jr., Korzelius CA, Lee EC, Steele GD, Jr., et al. (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci U S A 90: 3466–3470. 21. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H (2006) Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res 26: 1369–1376. 22. Baldus SE, Zirbes TK, Weingarten M, Fromm S, Glossmann J, et al. (2000) Increased galectin-3 expression in gastric cancer: correlations with histopatho- logical subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol 21: 258–266. 23. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, et al. (1994) Expression of a 31- kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56: 474–480. 24. Wang Y, Nangia-Makker P, Tait L, Balan V, Hogan V, et al. (2009) Regulation of prostate cancer progression by galectin-3. Am J Pathol 174: 1515–1523. Galectin-3 in Pancreatic Cancer 25. Cheong TC, Shin JY, Chun KH (2010) Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemothera- peutic agents. Cancer Sci 101: 94–102. 26. Honjo Y, Nangia-Makker P, Inohara H, Raz A (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7: 661–668. 27. Berberat PO, Friess H, Wang L, Zhu Z, Bley T, et al. (2001) Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49: 539–549. 28. Buchholz M, Braun M, Heidenblut A, Kestler HA, Kloppel G, et al. (2005) Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24: 6626–6636. 29. Lu Z, Hu L, Evers S, Chen J, Shen Y (2004) Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 4: 3975–3988. 30. Schaffert C, Pour PM, Chaney WG (1998) Localization of galectin-3 in normal and diseased pancreatic tissue. Int J Pancreatol 23: 1–9. 31. Vila MR, Lloreta J, Schussler MH, Berrozpe G, Welt S, et al. (1995) New pancreas cancers cell lines that represent distinct stages of ductal differentiation. Lab Invest 72: 395–404. 32. Taniguchi S, Iwamura T, Katsuki T (1992) Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis 10: 259–266. 33. Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. Nucleic Acids Res 17: 6419. 34. Ellenrieder V, Buck A, Harth A, Jungert K, Buchholz M, et al. (2004) KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk- MAPK in pancreatic cancer cells. Gastroenterology 127: 607–620. 35. Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, et al. (2003) SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res 63: 4945–4951. 36. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, et al. (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85: 545–554. 37. Califice S, Castronovo V, Bracke M, van den Brule F (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23: 7527–7536. 38. Dumic J, Dabelic S, Flogel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760: 616–635. 39. Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, et al. (2011) Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of beta-catenin. Int J Cancer (Epub ahead of print; doi: 10.1002/ijc.25946). 40. Jiang HB, Xu M, Wang XP (2008) Pancreatic stellate cells promote proliferation and invasiveness of human pancreatic cancer cells via galectin-3. World J Gastroenterol 14: 2023–2028. 41. Senapati S, Chaturvedi P, Chaney WG, Chakraborty S, Gnanapragassam VS, et al. (2011) Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res 17: 267–274. 42. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, et al. (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarci- noma of the pancreas. Clin Cancer Res 8: 2570–2575. PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e20859